Clinical Scorecard: Urinary Metabolites Associated with Suspected Community-Acquired Pneumonia
At a Glance
Category
Detail
Condition
Community-Acquired Pneumonia (CAP) in children
Key Mechanisms
Host-pathogen interaction produces unique urinary metabolic profiles detectable by metabolomics
Target Population
Children aged 3 months to 12 years with suspected CAP and community-based controls
Care Setting
Emergency department and community ambulatory settings
Key Highlights
Urine metabolite concentrations can accurately discriminate children with suspected CAP from healthy controls with high AUC (0.97–0.99).
Metabolite-only model identified key discriminatory metabolites including 2-aminobutyrate, fumarate, hypoxanthine, acetone, leucine, quinolinate, valine, O-acetylcarnitine, citrate, and trigonelline.
Combined clinical and metabolite model improved discrimination and included additional metabolites and clinical features such as corticosteroid use, fever, cough, rapid breathing, and wheezing.
Guideline-Based Recommendations
Diagnosis
Consider metabolomic urine testing as a noninvasive adjunct to improve diagnostic accuracy of pediatric CAP.
Use clinical signs and symptoms in combination with metabolite profiles to enhance discrimination of CAP from other respiratory infections.
Management
Current management guided by clinical assessment; metabolomics may inform future diagnostic tools but require further validation.
Monitoring & Follow-up
Monitor clinical signs such as fever, respiratory rate, and oxygenation; metabolite profiles are investigational and not yet for routine monitoring.
Risks
Misdiagnosis due to nonspecific clinical features and poor interrater reliability of chest radiographs.
Potential for over- or under-treatment without accurate diagnostic biomarkers.
Patient & Prescribing Data
Children aged 3 months to 12 years presenting with suspected CAP in emergency settings
Clinical factors such as corticosteroid and albuterol use were associated with CAP diagnosis; metabolomic profiles may guide future personalized treatment decisions.
Clinical Best Practices
Use a combination of clinical evaluation and emerging metabolomic biomarkers to improve diagnostic accuracy for pediatric CAP.
Recognize limitations of chest radiographs and nonspecific clinical signs in diagnosing CAP.
Ensure exclusion of children with immunodeficiency, chronic pulmonary or cardiac disease, or recent hospitalization to reduce confounding in diagnosis.
Support further validation studies of urinary metabolite biomarkers before clinical implementation.
by Lilliam Ambroggio, Todd A Florin, Kayla Williamson, Grace Bosma, Brandie D Wagner, Larisa Yeomans, Jae Hyun Kim, Heidi Sucharew, Maurizio Macaluso, Richard M Ruddy, Kathleen A Stringer, Samir S Shah
Chemsex at the pharmacy counter. Gut bacteria tracking helmet impacts. PMD predicting psychiatric illness bidirectionally. This week's research keeps landing in the same uncomfortable place: medicine is improvising.
